Opvia

Opvia reduce the time taken to develop bio-processes by 10X, while increasing product quality and enabling reduced production costs. We achieve this by offering a platform which combines non-invasive in situ data acquisition with proprietary models and ML. Advanced therapeutics such as cell and gene therapies will provide cures to currently incurable diseases, and synthetic biology will revolutionise industrial manufacturing, energy and food production. However, the cost of production is preventing these technologies from reaching scale. Opvia are positioned to enable the biotech revolution. Will Moss read Chemical Engineering and Biotechnology at Cambridge, where he found he had an affinity for process optimisation. He developed this further working as a data scientist, before harnessing his commercial skills building his first startup. Will excels at sales and loves to code. Jonathan Dench has a PhD and postdoc from Imperial College London. There he developed non invasive optical techniques at the edge of the hardware limit, and has 3 publications in Tier 1 journals. He excels at designing and building systems from the ground up.